ARTICLE
11 November 2016

Victory For A Healthcare Company In The First Pharmaceutical Product Liability Class Action Trial In Canada

MT
McCarthy Tétrault LLP
Contributor
McCarthy Tétrault LLP provides a broad range of legal services, advising on large and complex assignments for Canadian and international interests. The firm has substantial presence in Canada’s major commercial centres and in New York City, US and London, UK.
On October 19, 2016, the Superior Court of Québec released the first ever decision of a Canadian Court ruling on the merits of a pharmaceutical product liability common issues trial.
Canada Litigation, Mediation & Arbitration
To print this article, all you need is to be registered or login on Mondaq.com.

On October 19, 2016, the Superior Court of Québec released the first ever decision of a Canadian Court ruling on the merits of a pharmaceutical product liability common issues trial. In this decision [2016 QCCS 5083], the Plaintiffs were alleging that the healthcare company was responsible for psychiatric reactions experienced by the class members while taking an antibiotic.

The healthcare company retained McCarthy Tétrault LLP after certification of the class action by the Superior Court of Québec.

Justice Suzanne Hardy-Lemieux dismissed the action, concluding that the Plaintiffs had not met their burden of demonstrating that the antibiotic was the cause of the psychiatric reactions suffered by the class members. She stated that in the presence of strong evidence demonstrating the absence of causation, the Court could not base its decision on coincidental events that reveal, at best, low possibilities of causation. More specifically, Justice Hardy-Lemieux concluded that because of the blood-brain barrier protection, there was a minimal possibility that the drug could reach the brain and induce psychiatric reactions.

There are several takeaways in this judgment:

  • The inclusion of ²adverse reactions² in the Product Monograph is not proof that causation is recognized by the manufacturer;
  • The use of the Naranjo scale as well as case reports are inappropriate and insufficient to establish causation between a drug and adverse events; and
  • Individuals who consume generic versions of a drug have no claim against the manufacturer of the innovator drug due to the lack of connection at law.

This case is a reminder that once a class action is certified, Plaintiffs, on the merits, still have the onus to establish causation on the balance of probabilities. In a pharmaceutical product liability case, such demonstration needs to be based on solid scientific and expert evidence in order to be successful.

To view original article, please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
11 November 2016

Victory For A Healthcare Company In The First Pharmaceutical Product Liability Class Action Trial In Canada

Canada Litigation, Mediation & Arbitration
Contributor
McCarthy Tétrault LLP provides a broad range of legal services, advising on large and complex assignments for Canadian and international interests. The firm has substantial presence in Canada’s major commercial centres and in New York City, US and London, UK.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More